The generated CRAd-IL24 and CRAd-IN4 were tested along with control CRAd vector to validate hypothesis that arming Ad5/3Δ24 with IL-24 or ING4 therapeutic payload may improve oncolytic CRAd potency following infection ovarian cancer cells in vitro and in vivo. Here, ING4 is linked to ovarian cancer.